A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman

Research output: Contribution to journalArticlepeer-review

Abstract

Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged $65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to first-line therapy with azacitidine 75 mg/m2 on days 1 through 7 with (Arm A, n 5 64) or without (Arm B, n 5 65) durvalumab 1500 mg on day 1 every 4 weeks. Overall response rate (complete response [CR] 1 CR with incomplete blood recovery) was similar in both arms (Arm A, 31.3%; Arm B, 35.4%), as were overall survival (Arm A, 13.0 months; Arm B, 14.4 months) and duration of response (Arm A, 24.6 weeks; Arm B, 51.7 weeks; P 5 .0765). No new safety signals emerged with combination treatment. The most frequently reported treatment-emergent adverse events were constipation (Arm A, 57.8%; Arm B, 53.2%) and thrombocytopenia (Arm A, 42.2%; Arm B, 45.2%). DNA methylation, mutational status, and PD-L1 expression were not associated with response to treatment. In this study, first-line combination therapy with durvalumab and azacitidine in older patients with AML was feasible but did not improve clinical efficacy compared with azacitidine alone. ClinicalTrials.gov: NCT02775903.

Original languageEnglish
Pages (from-to)2219-2229
Number of pages11
JournalBlood advances
Volume6
Issue number7
DOIs
StatePublished - 12 Apr 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML'. Together they form a unique fingerprint.

Cite this